Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial.

[Farooqji]

The molecule cystamine, and its reduced form cysteamine, act via a number of pathways identified as being critical to the pathogenesis of PD. In particular, these agents are capable of crossing the blood-brain barrier, promoting the secretion of neurotrophic factors, the inhibition of oxidative stress, the reduction of inflammatory responses and importantly, have already been trialed in humans for a number of other clinical indications. In the last decade, compelling evidence has been accumulated that both cystamine and cysteamine can halt, and even reverse, ongoing neurodegenerative processes in a number of different models of PD, and as such, should now be taken forward to clinical trials in PD

ncbi.nlm.nih.gov/pubmed/313...

[jimcaster]

So, are they actually going to proceed to human trials? They say someone should, but I'm unclear as to whether they are actually doing it. Did I miss something?

[Parkie-]

This is quite a statement:

"Our laboratory has accumulated compelling evidence that both cystamine and cysteamine can halt, and even reverse, ongoing neurodegenerative processes in a number of different models of PD, and as such, should now be taken forward to clinical trials in PD"

"And importantly, have already been trialed in humans for a number of other clinical indications"

[Xenos]

Cysteamine is already sold under the names of Cystagon and Procysbi (ER).

Both are used primarily for kidney disease, and in trial for Huntington disease..

[MarionP in reply to Xenos]

If it's already in trial, then it might just be easier to approve for trials and already has a potential market anyway, so it would appear to make some sense to do one.